AI English summary of an SEC filing — figures as filed
Ecolab said net sales for Q2 2025 increased $4,025.2 million, or 1%, diluted earnings per share were $1.84, or +8%, and adjusted diluted earnings per share were $1.89, or +13%.
Key points
AI summaryEcolab said net sales for Q2 2025 increased $4,025.2 million, or 1%, diluted earnings per share were $1.84, or +8%, and adjusted diluted earnings per share were $1.89, or +13%.
The company said reported operating income for Q2 was $710.1 million, or +8%, reported operating income margin was 17.6%, and organic operating income margin was 18.3%, up 170 basis points.
Ecolab maintained its full-year 2025 adjusted diluted earnings per share outlook at $7.42 to $7.62, or +12% to 15%, and said it expects third-quarter Q3 adjusted diluted earnings per share in the $2.02 to $2.12 range, or +10% to 16%.
The company said fixed currency operating income for Global Institutional & Specialty in Q2 was $359.4 million, or +9%, and Global Life Sciences operating income was $34.8 million, or +105%.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.
Q2 Net Sales $4,025.2 million, Diluted EPS $1.84
Ecolab said net sales for Q2 2025 increased $4,025.2 million, or 1%, diluted earnings per share were $1.84, or +8%, and adjusted diluted earnings per share were $1.89, or +13%.
Source · Based on the filing body and exhibits
Q2 Operating Income $710.1 million, Margin 17.6%
The company said reported operating income for Q2 was $710.1 million, or +8%, reported operating income margin was 17.6%, and organic operating income margin was 18.3%, up 170 basis points.
Source · Based on the filing body and exhibits
Full-Year 2025 and Q3 Adjusted EPS Outlook
Ecolab maintained its full-year 2025 adjusted diluted earnings per share outlook at $7.42 to $7.62, or +12% to 15%, and said it expects third-quarter Q3 adjusted diluted earnings per share in the $2.02 to $2.12 range, or +10% to 16%.
Source · Based on the filing body and exhibits
Q2 Segment Operating Income Changes
The company said fixed currency operating income for Global Institutional & Specialty in Q2 was $359.4 million, or +9%, and Global Life Sciences operating income was $34.8 million, or +105%.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…